Delivery Order SPE2DB20D6037-SPE2DB24FTVR9

Award Date 5/23/24
Potential Completion Date 5/24/24
Potential Value $3.4K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $3,780.52 contract is for the delivery of 100 units of the prescription drug Vyvanse 10 mg capsules. The delivery order is part of a larger $499,999,999 Indefinite Delivery Contract (IDC) held by DMS Pharmaceutical Group with the DLA under the SPE2DB program, which enables the DLA to issue firm fixed-price delivery...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, for the supply of Vyvanse 70 mg capsules. The total ceiling value of the award is $1,898.10, with a period of performance through May 1, 2024. This delivery order is part of a larger, single-award indefinite delivery contract (IDC) held by DMS Pharmaceutical Group with the DLA, valued at up to $499,999,999, which...
This is a firm fixed-price delivery order for $1,328.40 awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The order is for the supply of 4565583680 units of Vyvanse 40 mg capsules. This delivery order is part of a larger indefinite delivery contract (IDC) valued at up to $499,999,999 that DMS Pharmaceutical Group holds with the DLA under the SPE2DB program, which covers a broad range of pharmaceutical...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, for the supply of 4,565,166,332 units of the prescription medication Vyvanse 10 mg capsules. The order has a ceiling value of $1,293.00 and an ultimate completion date of July 17, 2024. This delivery order is part of a larger indefinite delivery contract (IDC) with DLA under the SPE2DB program, which has a total...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business, for the provision of 4,563,918 units of the pharmaceutical drug Vyvanse 20 mg capsules. The firm fixed-price contract is valued at $1,031.85 and has a period of performance through March 11, 2024. The award is issued under DMS Pharmaceutical Group's existing indefinite delivery vehicle (IDV) contract SPE2DB24D2106 with DLA, which has a total ceiling value of up...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $8,558.68 contract is for the delivery of 4,567,466,046 units of the prescription drug Vyvanse 10 mg capsules. The contract has an ultimate completion date of March 6, 2025 and is not associated with a set-aside designation. DMS Pharmaceutical Group Inc. holds a larger $499,999,999 Indefinite Delivery...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $2,715.64 contract is for the delivery of 100 units of the prescription drug Vyvanse 50 mg capsules. The contract is not associated with a set-aside designation. It is part of a larger $499,999,999 Indefinite Delivery Contract (IDC) held by DMS Pharmaceutical Group Inc. with the DLA under the SPE2DB program. This IDC...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $1,724 contract is for the delivery of 100 capsules of the medication Vyvanse (70 mg) with an ultimate completion date of December 4, 2023. DMS Pharmaceutical Group holds a significant $499,999,999 indefinite delivery contract (IDC) with the DLA under the SPE2DB program, which allows the DLA to issue firm fixed-price...
This is a firm fixed-price delivery order (SPE2DB20D6037|SPE2DB24FTVC9) awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $1,724.00 award is for the supply of 4,564,218,067 units of the prescription drug VYVANSE 10 MG CAPSULE 100S. This delivery order is part of a larger $499,999,999 indefinite delivery contract (IDC) held by DMS Pharmaceutical Group with the DLA under the SPE2DB program, which provides a...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $1,313.77 contract is for the supply of 4566838310 VYVANSE 50 MG CAPSULE 100S, with a performance period through January 6, 2025. DMS Pharmaceutical Group holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which allows the agency to issue delivery orders for a range of...
  • SPE2DB20D6037
    Indefinite Delivery Contract
  • SPE2DB20D6037-SPE2DB24FTVR9
    Delivery Order

This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract, valued at $3,448, is for the delivery of 100 units of 20 milligram Vyvanse capsules. This delivery order is part of a larger indefinite delivery contract (IDC) between DMS Pharmaceutical Group and the DLA, valued at up to $499,999,999, which runs through December 31, 2025. The IDC covers a wide range of pharmaceutical products, including common medications and specialized drugs, to support the recurring medical supply needs of Department of Defense healthcare facilities worldwide. This contract has no set-aside designation.

Generated 10/23/24, 9:27 AM